Abstract:Biliary tract cancers are molecularly and anatomically diverse cancers which include intrahepatic cholangiocarcinoma, extrahepatic (perihilar and distal) cholangiocarcinoma, and gallbladder cancer. While recognized as distinct entities, the rarer incidence of these cancers combined with diagnostic challenges in classifying anatomic origin has resulted in clinical trials and guideline recommended strategies being generalized patients with all types of biliary tract cancer. In this review, we delve into the unique aspects, subtype-specific clinical trial outcomes, and multidisciplinary management of patients with extrahepatic cholangiocarcinoma. When resectable, definitive surgery followed by adjuvant chemotherapy (sometimes with selective radiation/chemoradiation) is current standard of care. Due to high recurrence rates, there is growing interest in the use of upfront/neoadjuvant therapy to improve surgical outcomes and to downstage patients who may not initially be resectable. Select patients with perihilar cholangiocarcinoma are being successfully treated with novel approaches such as liver transplant. In the advanced disease setting, combination gemcitabine and cisplatin remains the standard base for systemic therapy and was recently improved upon with the addition of immune checkpoint blockade to the chemotherapy doublet in the recently reported TOPAZ-1 and KEYNOTE-966 trials. Second-line all-comer treatments for these patients remain limited in both options and efficacy, so clinical trial participation should be strongly considered. With increased use of molecular testing, detection of actionable mutations and opportunities to receive indicated targeted therapies are on the rise and are the most significant driver of improved survival for patients with advanced stage disease. Though these targeted therapies are currently reserved for the second or later line, future trials are looking at moving these to earlier treatment settings and use in combination with chemotherapy and immunotherapy. In addition to cross-disciplinary management with surgical, medical, and radiation oncology, patient-centered care should also include collaboration with advanced endoscopists, palliative care specialists, and nutritionists to improve global patient outcomes.

Advances in the Imaging Evaluation of Cholangiocarcinoma

Imaging diagnosis of pancreatic cancer and preoperative imaging evaluation of resectability and staging

Contrast-enhanced Multiple-Phase Imaging Features of Intrahepatic Mass-Forming Cholangiocarcinoma and Hepatocellular Carcinoma with Cirrhosis: A Comparative Study

Accurate imaging diagnosis and evaluation of pancreatic cancer

ULTRASONIC DIAGNOSIS OF EXTRAHEPATIC CHOLANGIOCARCINOMA

Surgical Techniques in the Radical Resection of Hilar Cholangiocarcinoma

Imaging Diagnosis and Interventional Treatment for the Primary Hepatocellular Carcinoma with Biliary Obstruction

Imaging Features Of Intrahepatic Mass-Forming Cholangiocarcinomas On Gd-Bopta-Enhanced Mri

Contemporary advances in the endoscopic management of cholangiocarcinoma: a review of accomplished milestones and prospective opportunities

CT diagnosis of hepatic cholangiocarcinoma

Application of AI on cholangiocarcinoma

Update on the Diagnosis and Treatment of Cholangiocarcinoma

[New Advances in the Diagnosis and Treatment of Intrahepatic Cholangiocarcinoma].

Evaluation of Surgical Approach for Extrahepatic Cholangiocarcinoma.

Current Standards, Multidisciplinary Approaches, and Future Directions in the Management of Extrahepatic Cholangiocarcinoma

Diagnosis and Treatment of Hepatic Cholangiocarcinoma: Report of 52 Cases.

Advances in targeted therapy of cholangiocarcinoma

Application of three-dimensional visualization technique in preoperative planning of progressive hilar cholangiocarcinoma

Advances in imaging diagnosis of mixed-type liver cancer

Recent Advances in Pathology of Intrahepatic Cholangiocarcinoma

Surgical treatment of hilar cholangiocarcinoma: progress and controversy